GLSI Greenwich LifeSciences Inc

$GLSI When we cracked $20 on Friday, we closed at $18.99. Today we cracked it again and closed at $19.48, so maybe next time we hold $20 and don't look back. $20.31 was our highest price since 7/16 and $19.48 is our highest close since 7/15. We will get news soon enough and any memory below $25 will seem like a bad dream. Until then, happy for the general uptrend, even if the close isn't always pretty. Let's do it again tomorrow.

$GLSI Only 7 weeks until Bio Europe. (FYI, it's been 6 weeks since this comment): CEO Snehal Patel commented, "We attended and presented at the BIO conference in June 2026 and plan to attend the BIO-Europe conference later this year, where strategic and financing transactions can be originated or concluded. With the further derisking of the Phase III clinical trial, more than doubling of enrollment and event rate, interest from leading clinicians and hospitals in up to 200 sites in the US and Europe, screening of over 1,500 patients, and the transformation of the interim analysis into a big pharma like study similar in design to recent large breast cancer studies, we are expecting a continued up-tick in the quantity and seriousness of such discussions."

$GLSI Calling for tomorrow being open label update day. Could be wrong but fun to guess.

$GLSI I am speculating that if the trial is successful the stock will eclipse the all-time high of $158.

$GLSI its the San Antonio Breast Cancer conference in December 2026. Snehal likes to release data around that time. i believe this move in related to re-pricing of that and a significantly improving technical picture. i believe the stock will re-test $70 and on positive ph 3 results could easily go to $200. herceptin revenue is 6 billion. if you give a modest 4 multiple that gives you a $1600 stock. assuming significant dilution, beyond what is projected, and you get a $800 stock.

$GLSI Not only is the share price disconnected from reality (market cap of $250M, 10% drop today on no volume or news) but the borrowing costs are disconnected as well. Current Short interest is the second largest on record, yet the cost to borrow has plunged to below 20%. In December when the short interest hit the highest ever, the cost to borrow was well into triple digits. So many things don’t make sense right now. I hope we get some real news that will get us back above $20 soon.

$GLSI $RARE Rare is trending #1 on approval. I don’t own it, but kinda disheartening for those shareholders. Our interim data soon. If it’s positive I would be shocked if we don’t gain 500% to 3,000% that day. It gained 3,500 on Phase 2. Very low float. Tight as c-suite shares locked. Shorts already shorted most if the shares…so that will help this rocked. And the Insider Buying in one for the record books. Take a look: Not one single sell. 👇👇👇

$GLSI looks like a few shorts don't want to hold through the weekend. I don't blame them for getting out now.

$GLSI if you think of your investment as a partnership instead of get rich quick plan your level of patience will grow exponentially.

$GLSI the advantage of having a CEO with so many shares in the company (and who has continued to buy) means he needs to sell the company in order to realise his wealth. Snehal has run the company extremely well since IPO. credit where credit is due.

$GLSI we only have 2-3 shorts in here talking sh!t , when it goes up , where are you? And this is nothing . I’m not selling until at least $150 a share.

$GLSI we are many months or longer away from true goal. Current ridiculously low price should move higher as we get inevitably closer

$GLSI having a mgmt and CEO like Snehal makes a big difference to stock price. big insider ownership, he’s continued to buy and he comes across as caring about shareholders significantly as a result.

$GLSI I'm hoping for a little something in my email to explain this. Thank God I have a strong heart! It's getting exciting in here again.

$GLSI Should hit $20 today. And the immune nit even a fraction of the interim data. I have a buddy in a wealth fund acclimating on a personal level privately. He uses his company resources for DD. He likes our chances. Let’s just say he is a bit late to the game compared to some of us, but of course he has a shit ton of shares. Don’t for get the best DD that crappy traders ignore: 👇👇👇

$GLSI Stock ridiculously underpriced so not believing this run-up is noise. I always say don't wait on data when execs hold huge amount of shares and continue buying as Snehal has

$GLSI you aint see nothing yet...its coming is it this time or next time? we dont know yet, but its coming

$GLSI i suspect the longs on this board will be right about glsi. big market opportunity, low market cap, loyal insiders who treat shareholders right not dilute them, most importantly care about patients. healthy stock pullback to 200 week MA. recently basing and now moving up again.

$GLSI at least you called the right day for this thing to sling shot- let's hope there is some news to follow this up.

$GLSI searched: there are several articles published today, September 17, 2026, specifically covering the new GLSI-100 data: Cancer Network — “Novel Immunotherapy Reduces Breast Recurrence Rates in Non-HLA-A*02 Population.” It reports the updated FLAMINGO-01 open-label data and the 0.7% annual recurrence rate versus 4% in KATHERINE, described as an 83% reduction. � Cancer Network OncLive — “GLSI-100 Yields Low Recurrence Rate in High-Risk HER2+ Breast Cancer After Perioperative Therapy.” This is particularly relevant because it discusses the 250-patient open-label cohort, the <1% recurrence rate, and the fact that the randomized, double-blind portion is still ongoing. � OncLive CURE — “New Data Show Immunotherapy Reduces Breast Cancer Recurrence by Over 80%.” It also covers today's update and emphasizes that the new data include another six months of follow-up.